An FDA advisory panel votes in favor of Theravance's (THRX) Breo Ellipta, saying the inhaler was safe and effective at treating COPD. The agency's pulmonary-allergy advisory committee is still reviewing the drug and has to vote on whether the product should be marketed, but today's positive vote makes it likely the panel will vote affirmatively to support approval. Shares remain halted.
An FDA advisory panel votes in favor of Theravance's (THRX) Breo Ellipta, saying the inhaler was...
From other sites
at CNBC.com (Jun 11, 2014)
at CNBC.com (Dec 6, 2013)
at CNBC.com (Sep 10, 2013)
at CNBC.com (Jun 24, 2013)
at CNBC.com (Apr 15, 2013)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs